지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.6
- 수록면
- 41 - 53 (13page)
이용수
초록· 키워드
오류제보하기
Biologics are large complex proteins that are created in living cells that may serve a variety of uses and functions. Biosimilars are drugs that are like biologics designed to be used as interchangeable drugs. Biologics are known to be effective in managing and treating different diseases but less accessible due to high cost. Biosimilars have the same structure and function as their reference biologic and are less costly and were introduced in to the biotechnology industry in 2006 as a competition to the pharmaceutical industry. In this review we have discussed about similarities and differences between Avastin a biologic from Genentech and its five FDA approved biosimilars that are available in the market. The active ingredient of Avastin is bevacizumab, a monoclonal antibody that is used in combination with other drugs for the treatment of many types of cancers, is the first FDA approved anti-angiogenesis drug. Bevacizumab targets VEGF that plays a role in blood vessel formation under hypoxic conditions. Our understanding of VEGF’s involvement in cancer growth has evolved over the years and we now know that VEGF modulates tumor-induced immunosuppression. Since bevacizumab has established efficacy for approved indications, it is expected to remain an important agent in cancer therapy and partner in novel targeted combination therapy.
목차
Abstract
1. INTRODUCTION
2. Manufacturing & Characterization Methods for Biosimilars
3. Role of VEGF (normal cell VS cancer cell)
4. Avastin (bevacizumab) and its biosimilars
5. Indications
6. Posology and Administration of Bevacizumab
7. Precautions and adverse reactions
8. Elimination
9. CONCLUSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
허셉틴과 바이오시밀러 신약
KSBB Journal
2024 .12
-
Potential and Solution of Plant Cells in Biologics Manufacturing
한국생물공학회 학술대회
2016 .04
-
Core Strengths as a Leader in Biosimilars
한국생물공학회 학술대회
2019 .04
-
Samsung Biologics Introduction: World Leading Biologics Contract Manufacturer
한국생물공학회 학술대회
2020 .10
-
RNAi Therapy with Tumor-targeted Delivery of Polymerized VEGF siRNA using Thiolated Glycol Chitosan Nanoparticles to Overcome Avastin Resistance in Cancer Treatment
한국고분자학회 학술대회 연구논문 초록집
2016 .10
-
Biologics come of Age: Y-Biologics’ Antibody Discovery Strategy
한국생물공학회 학술대회
2019 .04
-
Optimization of upstream process development for the charge variant control in Aflibercept biosimilar production
한국생물공학회 학술대회
2019 .10
-
Structure and function of vascular endothelial growth factor and its receptor system
BMB Reports
2018 .01
-
Competitiveness of Samsung Bioepis in the biosimilar business area
한국생물공학회 학술대회
2018 .10
-
Responsive Polymeric Carriers for Biologic Drug Delivery
한국고분자학회 학술대회 연구논문 초록집
2016 .10
-
심근경색 조직재생을 위한 VEGF 나노입자 방출 약물 전달 패치
한국생산제조학회 학술발표대회 논문집
2022 .07
-
Loss of phospholipase D2 impairs VEGF-induced angiogenesis
BMB Reports
2016 .01
-
암 치료를 위한 항체치료제에 대한 고찰: 면역항암제
KSBB Journal
2020 .06
-
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-approved Drugs
한국생물공학회 학술대회
2020 .06
-
CLEC4a as a novel therapeutic target in angiogenesis: A new challenge with antibody-based targeting of VEGF
한국생물공학회 학술대회
2017 .10
-
융합 단백질을 이용한 재조합 인간 혈관내피세포 성장인자의 정제공정 개발
화학공학
2017 .01
-
구글 트렌드 빅데이터를 통한 바이오의약품의 시장 점유율 분석과 추정
산업경영시스템학회지
2020 .01
-
Doxorubicin and VEGF-targeting CRISPR/Cas9 Encapsulating Nanoparticles for Combinational Cancer Treatments
한국고분자학회 학술대회 연구논문 초록집
2022 .04
-
Mab Manufacturing Bioprocessing: Current Landscape and Future Innovations
한국생물공학회 학술대회
2019 .04
-
식물 유래 바이오의약품 생산을 위한 진공침윤 공정 기술 개발
한국생산제조학회 학술발표대회 논문집
2022 .12
최근 본 자료
댓글(0)
0